BioStack raises $9.5M to build medical AI training data from hospital records

Seed round and where the money goes

The seed round was led by Peak XV, Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures and Y Combinator. BioStack said the funds will support its continued expansion across the United States and international markets, the development of its technology platform and the growth of its engineering and research teams.

The company is led by CEO Sanat Mishra and CTO Parth Patwa. It announced the funding together with the launch of what it calls a data infrastructure network for medicine.

How BioStack builds its datasets

BioStack starts from a problem it says is common: patient histories and other clinical data are often fragmented across hospitals, providers and technology systems, leaving clinicians without a complete picture of a patient's treatment. The company builds workflows that bring together notes, labs, imaging, medications, treatments and outcomes from disparate health systems and geographies.

According to BioStack, these workflows are custom-built, protect patient privacy and follow the protocols of each individual provider. The company then creates proprietary datasets from the de-identified data it collects from each provider system. It says the datasets can support:

• medical research
• drug development
• training and evaluation of healthcare AI models

By linking biological and clinical data with treatment histories and long-term outcomes, BioStack says researchers can see what happened to a patient and how different interventions affected their health over time. The company describes this as a feedback loop between clinical care and medical innovation.

Imaging data and a cancer vaccine program in India

BioStack said it has combined more than several hundred thousand fragmented X-rays, MRIs and CT scans with pathology and clinical records. According to the company, the resulting dataset is a resource for training AI agents that help clinicians evaluate treatment options and likely patient outcomes.

In India, the company says it is helping connect cancer patients with an investigational cancer vaccine program. Patients' clinical data can support biotech companies' development efforts, while eligible patients may gain access to highly personalized investigational treatments.

Mishra said: "We're building the infrastructure that connects all of the clinical information and makes it useful, both for clinicians making decisions today and for the researchers and AI developers building the future of medicine."

What it means for medical AI developers

BioStack currently works with hospitals in the U.S., Brazil, India and Argentina, which it says gives it access to a diverse patient population and healthcare environments. The platform is designed to support medical AI model development and evaluation, clinical research, disease modeling, biomarker discovery, patient stratification and treatment-response analysis.

Pushpak Kedia, Vice President at Peak XV, said: "The next frontier of healthcare AI will depend not only on better models, but on access to high-quality, longitudinal data that reflects how patients are treated over time." He added that Peak XV believes BioStack "has the potential to become an important data layer for the next generation of medical AI."

For AI and biotech companies, the pitch is access to longitudinal, multi-source patient data that is otherwise scattered across institutions. The claims about dataset quality and scale come from the company and its investors, and the announcement gives no pricing or customer details.